Valen GroWorks Corp. (CSE: VGW) (OTC-QB: MYMSF) has announced this morning that the company has entered into an agreement with Harvest One (TSXV:HVT) to provide services in relation to the extraction of cannabinoids as well as the research & development of new cannabinoid derived products.
Valen GroWorks Corp. specializes in “proprietary extraction methodologies, distillation, cannabinoid isolation and purification.” Their company focuses on offering vertically integrated services related to extraction to companies involved in the cannabis and industrial hemp industries. Whereas, Harvest One has currently focused their business model on the development of cannabinoid focused wellness products to sell to the North American market.
Under the terms of this new agreement the two companies both have something to offer the other. Valen GroWorks Corp. will supply services to Harvest One that will allow the company to continue to develop an entensive product line. Cannabinoid derived products such as beverages, topicals, vape pens, and nutraceuticals.
“We are excited for the opportunity to utilize our extraction services and R&D technology platform to support Harvest One in delivering innovative, high quality consumer packaged goods to the market,” said Tyler Robson, CEO of Valens.
You may be interested
Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio OregonEditor - November 27, 2018
Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…
Wayland Group Enters UK Cannabis Market with Theros Pharma AcquisitionEditor - November 26, 2018
Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…
GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical TrialsEditor - November 26, 2018
GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…